LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

MicroRNA Studies to Be Enhanced by a New Line of Anti-miRNA Tools

By LabMedica International staff writers
Posted on 13 Feb 2014
Image: An artist's rendition of a Lentivirus expression vehicle (Photo courtesy of AMS Biotechnology ).
Image: An artist's rendition of a Lentivirus expression vehicle (Photo courtesy of AMS Biotechnology ).
A novel line of ready-to-use lentiviral expression vehicles provides microRNAs (miRNAs) and miRNA inhibitors for use as tools for the study of miRNAs and their role in various disease processes.

Lentiviruses, which are members of a subfamily of the retrovirus family, can deliver significant amounts of genetic information into host cells and integrate it into the cellular genome. Genetically engineered lentiviruses are therefore used as one of the most efficient tools of gene delivery. These modified lentiviruses contain a viral promoter that is used to control the expression of a transgene or shRNA but no residual virulence genes. Together with several other security modifications, this ensures their safe use in the laboratory.

MiRNAs comprise a family of small noncoding 19- to 25-nucleotide RNAs that regulate gene expression by targeting mRNAs in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer.

Anti-miRNAs are miRNA inhibitors that are short RNA molecules complementary to the mature miRNA sequence. Anti-miRNA binds to endogenous miRNA and inhibits or down-regulates specific miRNAs. MiRNA inhibitors also show potential as therapeutic agents for some biological malfunctions.

AMS Biotechnology (Abingdon, United Kingdom) has introduced a range of ready-to-use human and mouse Lentivirus products for miRNA and anti-miRNA expression. This range of miRNA inhibitors was produced from optimally designed anti-miRNA lentivectors. AMS Biotechnology's anti-miRNA lentivectors were carefully designed for highest anti-miRNA expression levels with precise promoter transcription position, and to favor the antisense strand for RNA-induced silencing complex (RISC) processing.

Related Links:

AMS Biotechnology


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Human Estradiol Assay
Human Estradiol CLIA Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more